The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia
Abstract
OBJECTIVE: Dopamine D2 receptor occupancy measurements provide a valid predictor of antipsychotic response, extrapyramidal side effects, and elevation of prolactin levels. The new antipsychotics clozapine, risperidone, and olanzapine obtain antipsychotic response with few extrapyramidal side effects and little prolactin elevation. The purpose of this study was to compare the D2 and serotonin 5-HT2 receptor occupancies of these drugs in patients receiving multiple-dose, steady-state regimens. METHOD: Forty-four patients with schizophrenia (16 taking risperidone, 2-12 mg/day; 17 taking olanzapine, 5-60 mg/day; and 11 taking clozapine, 75-900 mg/day) had their D2 and 5-HT2 occupancies determined with the use of [11C]raclopride and [18F]setoperone, respectively, and positron emission tomography imaging. RESULTS: Clozapine showed a much lower D2 occupancy (16%-68%) than risperidone (63%-89%) and olanzapine (43%-89%). Risperidone and olanzapine gave equal D2 occupancies at doses of 5 and 20 mg/day, respectively. All three drugs showed greater 5-HT2 than D2 occupancy at all doses, although the difference was greatest for clozapine. CONCLUSIONS: Clozapine, at doses known to be effective in routine clinical settings, showed a D2 occupancy clearly lower than that of typical antipsychotics, while risperidone and olanzapine at their usual clinical doses gave the same level of D2 occupancy as low-dose typical antipsychotics. The results also suggest that some previous clinical comparisons of antipsychotics may have been confounded by different levels of D2 occupancy. Clinical comparisons of these drugs, matching for D2 occupancy, may provide a better measure of their true "atypicality" and will help in understanding the contribution of non-D2 receptors to antipsychotic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Deficit and nondeficit forms of schizophrenia: the concept
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.5.578 · Cited by 1,332
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Antischizophrenic Drugs: Chronic Treatment Elevates Dopamine Receptor Binding in Brain
Burt, D. R., Creese, I., & Snyder, S. H. (1977) · Science · doi:10.1126/science.847477 · Cited by 1,024
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
CHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MacEWAN, G. W., LABELLE, A., BEAUCLAIR, L., & ARNOTT, W. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
Self-citationArvanitis, L. A., & Miller, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00190-x · Cited by 803
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Cited by
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Self-citationKapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Self-citationMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Half a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638
Self-citationAntipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management
Haddad, P. M., & Wieck, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00003 · Cited by 634
Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500516x · Cited by 605
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
Schizophrenia: overview and treatment options.
(2014) · PubMed Central · Cited by 533
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
Kapur, S., VanderSpek, S. C., Brownlee, B. A., & Nobrega, J. N. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046987 · Cited by 479
Self-citationMechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia
Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., & H??schl, C. (2006) · CNS Drugs · doi:10.2165/00023210-200620050-00004 · Cited by 461
Dorph-Petersen, K.-A., Pierri, J. N., Perel, J. M., Sun, Z., Sampson, A. R., & Lewis, D. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300710 · Cited by 437
Kapur, S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.553 · Cited by 396
Self-citationKapur, S., & Remington, G. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390
Self-citationKaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
Conley, R. R., & Mahmoud, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.765 · Cited by 334
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia
Kapur, S., & Remington, G. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.503 · Cited by 324
Self-citationBurns, H. D., Van Laere, K., Sanabria-Bohórquez, S., Hamill, T. G., Bormans, G., Eng, W.-S., Gibson, R., Ryan, C., Connolly, B., Patel, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703472104 · Cited by 315
Yokoi, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00304-4 · Cited by 313
Effects of Newer Antipsychotics on Extrapyramidal Function
Tarsy, D., Baldessarini, R. J., & Tarazi, F. I. (2002) · CNS Drugs · doi:10.2165/00023210-200216010-00003 · Cited by 313
Tolerability of Atypical Antipsychotics
Stanniland, C., & Taylor, D. (2000) · Drug Safety · doi:10.2165/00002018-200022030-00004 · Cited by 303
Targeting the dopamine D2receptor in schizophrenia
Seeman, P. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.4.515 · Cited by 302
Ondo, W. G., Tintner, R., Dat Voung, K., Lai, D., & Ringholz, G. (2005) · Movement Disorders · doi:10.1002/mds.20474 · Cited by 297
Schizophrenia: from phenomenology to neurobiology
Wong, A. H. C., & Van Tol, H. H. M. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(03)00035-6 · Cited by 280
Schizophrenia: More dopamine, more D 2 receptors
Seeman, P., & Kapur, S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.7673 · Cited by 279
Self-citationClozapine alone versus clozapine and risperidone with refractory schizophrenia
Honer, W. G., Thornton, A. E., Chen, E. Y. H., Chan, R. C. K., Wong, J. O. Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053222 · Cited by 277
Marek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Li, P., L. Snyder, G., & E. Vanover, K. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160608084834 · Cited by 266
Freudenreich, O., & Goff, D. C. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.01331.x · Cited by 259
Wadenberg, M. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00261-5 · Cited by 256
Paliperidone for schizophrenia
Dolder, C., Nelson, M., & Deyo, Z. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070261 · Cited by 254
Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237
All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors
Seeman, P. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00162.x · Cited by 228
“Antipsychotic occupancies of D2 are between 60% and 80% [83,84], with the exception of the aripiprazole which internalizes D2 receptors into the cytoplasm, and occupies D2 in excess of 90%.”
BackgroundAbi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179
KUROKI, T., NAGAO, N., & NAKAHARA, T. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00910-2 · Cited by 146
McClay, J. L., Adkins, D. E., Åberg, K., Bukszár, J., Khachane, A. N., Keefe, R. S. E., Perkins, D. O., McEvoy, J. P., Stroup, T. S., Vann, R. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.193 · Cited by 124
Gefvert, O., Eriksson, B., Persson, P., Helldin, L., Björner, A., Mannaert, E., Remmerie, B., Eerdekens, M., & Nyberg, S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004924 · Cited by 119
Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents
Naidoo, U., Goff, D. C., & Klibanski, A. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00129-4 · Cited by 113
SPORN, A. L., VERMANI, A., GREENSTEIN, D. K., BOBB, A. J., SPENCER, E. P., CLASEN, L. S., TOSSELL, J. W., STAYER, C. C., GOCHMAN, P. A., LENANE, M. C., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31812eed10 · Cited by 107
Sun, W., Ginovart, N., Ko, F., Seeman, P., & Kapur, S. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.456 · Cited by 99
Self-citationUchida, H., Takeuchi, H., Graff-Guerrero, A., Suzuki, T., Watanabe, K., & Mamo, D. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218d339 · Cited by 94
Fonseka, T. M., Richter, M. A., & Müller, D. J. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0510-8 · Cited by 93
Konarzewska, B., Wołczyński, S., Szulc, A., Galińska, B., Popławska, R., & Waszkiewicz, N. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.08.015 · Cited by 70
The potential role of lamotrigine in schizophrenia
Large, C. H., Webster, E. L., & Goff, D. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0020-9 · Cited by 69
Obsessive-compulsive symptoms in schizophrenia: an up-to-date review of literature
Tezenas du Montcel, C., Pelissolo, A., Schürhoff, F., & Pignon, B. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1051-y · Cited by 61
“The role of dopamine in the pathophysiology of OCD has been hypothesized [66], and confirmed by growing evidence supporting the anti-obsessive effect of various SGAP, with a specific efficacy of aripiprazole on OCS [67–71].”
ResultMargolese, H. C., Chouinard, G., Beauclair, L., & Bélanger, M.-C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00003 · Cited by 61
Byerly, M. J., Nakonezny, P. A., Bettcher, B. M., Carmody, T., Fisher, R., & Rush, A. J. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.04.005 · Cited by 55
“In contrast, risperidone and olanzapine produce high degrees of D2 receptor antagonism, occupying ≥70% of D2 receptors at clinically effective doses (Bench et al., 1993; Farde et al., 1992; Kapur et al., 1999).”
BackgroundCatafau, A. M., Perez, V., Plaza, P., Pascual, J.-C., Bullich, S., Suarez, M., Penengo, M. M., Corripio, I., Puigdemont, D., Danus, M., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0540-y · Cited by 46
Szmulewicz, A., Samamé, C., Caravotta, P., Martino, D. J., Igoa, A., Hidalgo-Mazzei, D., Colom, F., & Strejilevich, S. A. (2016) · International Journal of Bipolar Disorders · doi:10.1186/s40345-016-0047-3 · Cited by 28
Role of aripiprazole in treating mood disorders
García-Amador, M., Pacchiarotti, I., Valentí, M., Sanchez, R. F., Goikolea, J. M., & Vieta, E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.12.1777 · Cited by 25
Kalkman, H. O. (2023) · Biomedicines · doi:10.3390/biomedicines11030806 · Cited by 18
Metadata
- Authors
- Kapur, S., Zipursky, R. B., & Remington, G.
- Venue
- American Journal of Psychiatry
- Published
- 1999-02-01
- Volume
- 156
- Issue
- 2
- Pages
- 286-293
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2155342545
- Cited by
- 712
- References
- 45
- FWCI
- 31.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.